Pharma
Glenmark launches SUTIB at affordable cost to reduce risk of kidney cancer progression by 58%
NE BUSINESS BUREAU MUMBAI, FEB 17 Glenmark Pharmaceuticals launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney...
Read more
Alembic Global Holding SA gets USFDA nod for pulmonary arterial hypertension treatment injection
NE BUSINESS BUREAU NEW DELHI, FEB 12 Drug firm Alembic Pharmaceuticals on Friday said its arm, Alembic Global Holding SA,...
Read more
Q3 results: Torrent Pharma net profit up 18 pc at Rs 297 cr
NE NEWS SERVICE NEW DELHI, FEB 8 Drug firm Torrent Pharmaceuticals on Monday reported an 18.32 percent rise in its...
Read more
Alembic Pharma gets five observations from USFDA for Gujarat facility
NE BUSINESS BUREAU NEW DELHI, FEB 8 Alembic Pharmaceuticals on Monday said the US health regulator has made five observations...
Read more
Q3 results: Cadila Healthcare net profit up 41 pc to Rs 527 cr
NE BUSINESS BUREAU NEW DELHI, FEB 5 Drug firm Cadila Healthcare on Friday reported a 41 percent rise in its...
Read more
Q3 results: Lincoln Pharma PAT rises 31 pc to Rs 13.37 crore
NE BUSINESS BUREAU AHMEDABAD, FEB 2 Lincoln Pharmaceuticals Limited, on Tuesday, has reported net profit of Rs 13.37 crore for...
Read more
Reliance signs US $15 mn deal with Israeli firm to distribute COVID-19 breath test kit
NE BUSINESS BUREAU JERUSALEM, JAN 27 Reliance Group has signed a US $15 million deal with Israeli company Breath of...
Read more
Zydus Cadila says ‘positive results’ from phase 2 studies of COVID-19 drug Desidustat in Mexico
NE BUSINESS BUREAU NEW DELHI, JAN 25 Drug firm Zydus Cadila on Monday said it has received positive results from...
Read more
Zydus Cadila gets USFDA nod for thyroid drug
NE BUSINESS BUREAU NEW DELHI, JAN 23 Drug firm Zydus Cadila has received final approval from the US health regulator...
Read more
Q3 results: Alembic Pharma net profit up 25 pc to Rs 293 cr
NE BUSINESS BUREAU NEW DELHI, NOV 19 Drug firm Alembic Pharmaceuticals on Tuesday reported a 24.92 percent rise in its...
Read more
